Tumor Antigen-Pulsed Dendritic Cell Vaccine for Treatment of Patients with Advanced Malignant Tumor:A Clinical Observation
ZHU Li-ming,ZHANG Yi-ping,WANG Xiao-jia,ZHONG Hai-jun,FAN Yun,YU Xin-min,DENG Qing-hua,KONG Xiang-ming,YING Jie-er,LI Tie,LOU Guang-yuan,WU Zhi-bing,TANG Zhong-zhu,MA Sheng-ling
DOI: https://doi.org/10.3872/j.issn.1007-385x.2007.06.014
2007-01-01
Chinese Journal of Cancer
Abstract:Objective: To observe the safety and clinical efficacy of tumor antigen-pulsed dendritic cell(DC) vaccine in treatment of advanced malignant tumor.Methods: Ninety-one patients with non-small cell lung cancer,colon and rectal cancer,melanoma,renal carcinoma,breast cancer and other malignant tumors were enrolled in this study.All patients met the selecting standard and signed informed consent.Human dendritic cells were obtained from peripheral blood monocytes by culturing them with granulocyte macrophage-colony stimulating factor and interleukin-4.DC vaccine was prepared from tumor antigen pulsed immature dendritic cells in vitro.Patients received the vaccine therapy once every week and one cycle was defined as once every week for 3 weeks.Results: All the patients received 96 cycles of DC vaccine treatment.Symptoms of toxicity included fever,shivering,aching pain of muscle,asthenia,itching,stifle and transient fatigue;most of the symptoms automatically recovered.Clinical efficacy of the treatment was evaluated in 76 patients.Thirty-one of the 76 patients were stable after treatment and 45 were in progressive situation,with the clinical benefiting rate being 40.8%.Eighty-five patients were followed up.The median time for progression was 2.6 months;the overall survival time was 0.9-30.6 months;and the median survival period was 4.5 months,with the one year survival rate being 9.2%.Conclusion: The results suggest that the DC vaccine therapy is well tolerated in treating patients with advanced malignant tumors and has satisfactory clinical benefit;the clinical value of DC vaccine therapy needs to be further observed.